The use of antibiotics in poultry farming has been associated with bacterial resistance in humans, leading to a ban on their inclusion in chicken diets. Therefore, the objective was to evaluate the effects of probiotics and β-mannanase on the growth performance and intestinal health of broiler chickens challenged by Eimeria maxima and Clostridium perfringens. For this, 2100 one-day-old male Ross 308 chicks were used. The treatments were as follows: T1—Negative control (NC) unchallenged birds; T2—Positive control (PC) challenged with E. maxima + C. perfringens; T3—PC + Antibiotic (Enramycin 8%-125 g/ton); T4—PC + β-mannanase (HemicellHT; 300 g/ton); T5—PC + probiotic (ProtexinTM; 150 g/ton); T6—PC + β-mannanase + probiotic. Significant differences (p < 0.05) were observed from 1 to 42 days in the variables body weight, body weight gain and feed intake, and the NC treatment presented higher values compared to the PC and PC + probiotic groups. The villus/crypt ratio in the duodenum increased in the PC + β-man + prob treatment, differing from the NC, PC and PC + probiotic (p < 0.05) treatments. The use of β-mannanase, probiotics or both together is effective to mitigate the effects of production challenges, through the maintenance of the intestine by modulating action on the cecum microbiome and intestinal morphometry.
No takes yet. Share an insight, caveat, or question.
Maria et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: